The effectiveness of treatment for depression is not in doubt, and common humanity would indicate that it should be provided to those that need it.
However, in this paper I argue that the existence of effective treatment should not be regarded as a sufficient condition for the extension of insurance cover.
This is because insurance coverage cannot guarantee that treatment is delivered effectively, nor that it is given to the right people ; neither does it lend itself to the maximization of cost-effectiveness.
Payment systems must take account of these considerations.
Mots-clés Pascal : Etat dépressif, Trouble humeur, Analyse coût, Traitement, Economie santé, Assurance maladie, Efficacité traitement, Evaluation, Financement, Santé mentale, Etats Unis, Amérique du Nord, Amérique, Homme, Etude critique, Remboursement
Mots-clés Pascal anglais : Depression, Mood disorder, Cost analysis, Treatment, Health economy, Health insurance, Treatment efficiency, Evaluation, Financing, Mental health, United States, North America, America, Human, Critical study
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0488066
Code Inist : 002B18H05B. Création : 01/03/1996.